Trial Search Results

A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

This is open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors that will be conducted in 3 parts (dose escalation, expansion to solid tumors, and expansion to T cell lymphomas). Part 3 Expansion will be conducted at Stanford to further evaluate the safety and efficacy in patients with T-cell lymphomas.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Drug: TTI-621
  • Drug: TTI-621 plus Rituximab
  • Drug: TTI-621 plus Nivolumab


Phase 1


Inclusion Criteria:

   1. Advanced measurable malignancy

   2. Adequate hematologic status

   3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1
   prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will
   be considered a systemic therapy. Local radiation and topical agents are not systemic

   4. Adequate coagulation function

   5. Adequate hepatic function

   6. Adequate renal function

Exclusion Criteria:

   1. Known, current central nervous system disease involvement or untreated brain

   2. Allogeneic transplant within 30 days prior to the planned start of treatment or
   subjects with active graft-vs-host disease with the exception of Grade 1 skin

   3. History of hemolytic anemia or bleeding diathesis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Elle (Hyunjin) Kim
Not Recruiting